ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 19, 2018, by ADMA Biologics, Inc. (the "Company"), an emerging growth company incorporated in Delaware. The report details material definitive agreements and asset transfers involving the Company, its wholly-owned subsidiary ADMA BioManufacturing, LLC, and Biotest Pharmaceuticals Corporation ("BPC") in connection with the divestiture of BPC's U.S. assets to CREAT Group Corporation.
Key Financial Metrics and Agreements
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period. However, it outlines the following financial terms within new agreements:
- Loan Facility: A $15 million unsecured, subordinated loan agreement exists between the Company and BPC (now transferred to Biotest AG), bearing interest at 6% per annum with a five-year maturity.
- Plasma Supply Pricing: Amendments to plasma supply agreements include price protection mechanisms. If BPC fails to supply requested amounts, it must reimburse the Company for price differences incurred when sourcing from third parties (specifically within a "low double digit percentage" for hepatitis B plasma and "high double digit percentage" for Normal Source Plasma).
- Equity Transfer: BPC transferred 10,109,534 shares of the Company's common stock to the Biotest Divestiture Trust.
Material Changes and Transactions
The filing reports several material changes executed in July 2018:
- Amendment to Plasma Supply Agreement: Entered into on July 19, 2018, regarding hyperimmune plasma containing antibodies to the hepatitis B virus. It establishes reimbursement obligations for BPC if supply shortfalls occur and third-party pricing is unfavorable.
- Amendment to Plasma Purchase Agreement: Entered into on July 19, 2018, regarding Normal Source Plasma (NSP). It sets agreed supply amounts for calendar year 2019 and minimum supply percentages (high double digit) for 2020 and 2021, contingent on purchase orders and price negotiations.
- Voting Share Transfer: On July 24, 2018, BPC transferred its remaining holdings of 10,109,534 shares of Common Stock to the Biotest Trust. The Trust assumes all rights and obligations under the existing Stockholders and Registration Rights Agreements.
- Loan and Land Transfer: On July 20, 2018, BPC transferred the $15 million loan obligation to Biotest AG. Additionally, BPC transferred rights to "Undeveloped Real Property" to Biotest AG, subject to the Company's right of first offer to purchase the property in cash.
Outlook, Risks, and Contingencies
The filing highlights the following outlook and risk factors:
- Supply Security: The amendments to plasma agreements are designed to mitigate supply chain risks by ensuring price parity if BPC cannot meet volume requirements.
- Regulatory Compliance: The Biotest Trust is subject to U.S. securities laws by virtue of its ownership of the Company's Common Stock.
- Future Negotiations: The Company holds a right of first negotiation for the purchase of remaining shares held by the Biotest Trust for a 90-day period following the Voting Share Closing Date.
- Real Estate Option: The Company retains a right of first offer to purchase the Undeveloped Real Property for up to ten years from the Master Purchase Agreement closing date.
Key Facts for Investor Verification
- Verify the specific "low double digit" and "high double digit" percentage thresholds defined in the full text of the Plasma Supply and Purchase Agreement amendments.
- Confirm the status of regulatory approvals required for the Biotest Trust to hold the transferred Common Stock.
- Review the full text of the Assignment and Assumption Agreement (ADMA Loan) to understand any covenants or conditions attached to the $15 million loan now held by Biotest AG.
- Monitor the Company's next Quarterly Report on Form 10-Q for the full text of the amended plasma agreements.